期刊文献+

星点设计效应面法优化氟比洛芬纳米结构脂质载体凝胶剂的处方 被引量:7

Application of central composite design-response surface methodology to the formulation of flurbiprofen-loaded nanostructured lipid carriers gel
原文传递
导出
摘要 目的采用星点设计法以经皮累计渗透量为指标优化氟比洛芬纳米结构脂质载体凝胶剂的处方。方法以经皮累积渗透量为评价指标,考察了凝胶基质量(x1)、氮酮用量(x2)和丙二醇用量(x3)对氟比洛芬纳米结构脂质载体凝胶剂性质的影响。用多元线性方程和二次多项式描述经皮累积渗透量和3个影响因素之间的数学关系,根据经皮累积渗透量的最佳数学模型描绘效应面,选择最佳处方,并进行预测分析。结果三个影响因素和经皮累积渗透量之间存在定量关系。优选的最佳处方:卡波姆940为0.15 g、氮酮为0.70 g,丙二醇为1.50 g。优化处方各指标的预测值和目标值接近。结论所建立的模型预测性良好,可用于预测和优化氟比洛芬纳米结构脂质载体凝胶剂处方。 Objective To prepare and opimize the flurbiprofen-loaded nanostructured lipid carders gel using central composite design-response surface methodology in order to obtain a formulation with optimized properties. Methods The effects of formulation variables (amount of Carbopol 940, amount of azone and amount of propylene glycol) on a number of response variables were systemically investigated. The response variables were cumulative amount of percutaneous penetration. A desirability function that combines the response variable was constructed. A second-order polynomial equation was fitted to the data, and the resulting eqution was used to predict the responses in the optimal region. Results The response variable was found to be highly dependent on the formulation variables. It was found that optimum cumulative amount of percutaneous penetration of the flurbiprofen-loaded nanostructured lipid carriers gel can be obtained at 0. 15 g of Carbopol 940,0. 70 g of azone, 1.50 g of propylene glycol. The experimental values of the response variables highly agreed with the predict values. Conclusions Central composite design-response surface methodology is successfully used to optimize the preparation of flurbiprofen-loaded nanostructured lipid carriers gel. Overall desirability can be used to represent the most desirable variables in experimental design.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2012年第3期176-180,共5页 Journal of Shenyang Pharmaceutical University
关键词 氟比洛芬 纳米结构脂质载体 凝胶剂 星点设计 效应面 flurbiprofen nanostructured lipid carders gel central composite design response surface methodology
  • 相关文献

参考文献15

  • 1FINNIN B C,MORGAN T M.Transdermal penetrationenhancers:applications,limitations,and potential[J].JPharm Sci,1999,88(10):955-958.
  • 2MLLER R H,RADTNK M,WISSING S A.Nanostructured lipid matrices for improved microencap-sulation of drugs[J].Int J Pharm,2002,242(1-2):121-128.
  • 3üNER M,WISSING S A,YENER G,et al.Solid lipidnanoparticles(SLN)and nanostructured lipid carriers(NLC)for application of ascorbyl palmitate[J].Pharmazie,2005,60(8):577-582.
  • 4TEERANACHAIDEEKUL V,MüLLER R H,JUNYA-PRASERT V B.Encapsulation of ascorbyl palmitate innanostructured lipid carriers(NLC)——effects of for-mulation parameters on physicochemical stability[J].Int J Pharm,2007,340(1-2):198-206.
  • 5SOUTO E B,WISSING S A,BARBOSA C M,et al.De-velopment of a controlled release formulation based onSLN and NLC for topical clotrimazole delivery[J].Int JPharm,2004,278(1):71-77.
  • 6SOUTO E B,MüLLER R H.SLN and NLC for topicaldelivery of ketoconazole[J].J Microencapsul,2005,22(5):501-510.
  • 7SONG Yi-fan,XIAO Chun-hong,MENDELSOHN R,et al.Investigation of iminosulfuranes as novel transder-mal penetration enhancers:enhancement activity andcytotoxicity[J].Pharm Res,2005,22(11):1918-1925.
  • 8TEERANACHAIDEEKUL V,SOUTO E B,JUNYA-PRASERT V B,et al.Cetyl palmitate-based NLC fortopical delivery of Coenzyme Q(10)-development,physicochemical characterization and in vitro releasestudies[J].Eur J Pharm Biopharm,2007,67(1):141-148.
  • 9SOUTO E B,MüLLER R H.The use of SLN andNLC as topical particulate carriers for imidazole anti-fungal agents[J].Pharmazie,2006,61(5):431-437.
  • 10吴伟,崔光华.星点设计-效应面优化法及其在药学中的应用[J].国外医学(药学分册),2000,27(5):292-298. 被引量:426

二级参考文献2

  • 1Sébastien Branchu,Robert T. Forbes,Peter York,H?kan Nyqvist. A Central Composite Design to Investigate the Thermal Stabilization of Lysozyme[J] 1999,Pharmaceutical Research(5):702~708
  • 2Emad Eldin Hassan,Roy C. Parish,James M. Gallo. Optimized Formulation of Magnetic Chitosan Microspheres Containing the Anticancer Agent, Oxantrazole[J] 1992,Pharmaceutical Research(3):390~397

共引文献441

同被引文献73

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部